Overview
- The Journal of the American Medical Association paper published Nov. 19, 2026 analyzed blood drawn while alive from 21 former football players who later donated their brains and found 18 had CTE, including 16 with high‑stage disease.
- Researchers reported that blood levels of endogenously cleaved microtubule‑binding region tau (eMTBR‑tau) were significantly higher in the players with high‑stage CTE than in those with low‑stage or no CTE.
- A separate study in the same JAMA issue using a different laboratory method at Washington University in St. Louis found related tau protein elevations, providing independent support for the BU findings.
- Authors and outside experts caution the result is preliminary because the sample is small, lacks broad age‑matched controls and could reflect selection bias in brain‑bank donors, and the test is not FDA approved or ready for clinical use.
- If larger, representative studies confirm the marker and combine it with other tests such as p‑tau217 to separate Alzheimer’s from CTE, a validated blood test could allow diagnosis in living people, enable clinical trials, and reshape prevention and care for people with repeated head impacts.